Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (2296)	7/23/2010 12:45:20 PM
From: richardred	Read Replies (2) \| Respond to of 7252

Why MATK is a Speculative buy for me? NBTY Agrees to Be Acquired by the Carlyle Group for $55.00 Per Share in Cash; Transaction Valued at $3.8 Billion; NBTY is a Leading Nutritional Supplement Company RONKONKOMA, N.Y., July 15, 2010 /PRNewswire via COMTEX/ -- NBTY, Inc. (NYSE: NTY), a leading global manufacturer and marketer of nutritional supplements, today announced the execution of a definitive merger agreement under which The Carlyle Group will acquire NBTY in a transaction valued at $3.8 billion. Under the terms of the merger agreement, Carlyle will acquire all of the outstanding common shares of NBTY for $55.00 per share in cash, representing a premium of approximately 57% over NBTY's average closing share price during the 30 trading days ended July 14, 2010.

To: richardred who wrote (2296)	12/21/2010 10:56:09 AM
From: richardred	Read Replies (1) \| Respond to of 7252

I Hit the Takeover bullseye today with MATK-Entered at 20.60-in July-Nice weighted position for me also. :+ ) DSM to buy US biotech company Martek for $1.09B Martek Biosciences accepts $1.09 billion cash bid from Dutch chemicals maker DSM ap On Tuesday December 21, 2010, 10:09 am AMSTERDAM (AP) -- Royal DSM NV, the world's biggest maker of vitamins, said Tuesday it will bid $1.09 billion (euro830 million) in cash for U.S. biotech firm Martek Biosciences Corp., in a management-endorsed buyout that would improve its presence on the American infant formula market. The Dutch chemicals company's $31.50 per share offer for Martek represents a 35 percent premium to Martek's closing price on Dec. 20. In U.S. premarket trading, Martek shares surged $8.04, or 34.4 percent, to $31.40. DSM, based in Heerlen, the Netherlands, makes nutritional supplements, fibers used in bulletproof vests, and ingredients used in vaccines, as well as industrial chemicals. DSM's CEO Feike Sijbesma said the purchase "will add a new growth platform to our nutrition business," while Martek would benefit from DSM's larger distribution network. Martek, based in Colombia, Maryland, sells nutritional oils, ingredients for infant formula and dietary supplements. Its customers include Danone, Nestle, Kellogg's and General Mills, among others. DSM said its offer will begin in mid-January and is conditional on receiving a majority of shares. It expects the deal to close sometime in the second quarter. DSM said the deal, which must also be approved by regulators, would add at least euro0.15 to annual per share earnings in the first year. Shares in DSM rose 4.5 percent to euro42.845 in Amsterdam. In November, DSM reported a third quarter net profit of euro79 million, or euro0.76 per share, on sales of euro2.15 billion. As of Tuesday, the company has a stockpile of more than euro2 billion in cash due to profits and recent sales of several low-margin businesses. Martek earlier this month reported a fiscal fourth-quarter loss of $6.2 million on higher costs and a hefty restructuring charge linked to the sale of assets at its Winchester, Ky., manufacturing facility. Revenue rose 36 percent to $119.1 million, on higher sales of nutritional ingredients and branded consumer health products. The results topped analysts' average estimates. finance.yahoo.com